Would you use PCC for clotting factor repletion in acute life threatening hemorrhage in a patient with elevated INR from coagulopathy of liver disease?

I do not use KCentra in this clinical situation.

Firstly, the INR is validated for vitamin K antagonists (VKA) therapy only. The VKAs inhibit the synthesis of factors II, VII, IX, and X while the liver produces more clotting factors such as fibrinogen, II, V, VII, IX, X, XI, XII, etc. The INR has no...

I do not routinely use KCentra for clotting factor repletion in patients with life-threatening hemorrhage due to coagulopathy of liver disease. KCentra (or prothrombin complex concentrate) is FDA approved for urgent reversal of coagulation factor deficiency induced by vitamin K antagonists, and ther...